.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Queensland Health
Cipla
Deloitte
Cerilliant
Covington
Farmers Insurance
UBS
Novartis
Accenture

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,022,340

« Back to Dashboard

Summary for Patent: 7,022,340

Title:Pharmaceutical composition as solid dosage form and method for manufacturing thereof
Abstract:The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof; wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.
Inventor(s): Lomryd; Hakan (Malmo, SE), Nicklasson; Helena (Malmo, SE), Olsson; Lars-Erik (Malmo, SE)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:10/626,857
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

No matches for this query

International Patent Family for Patent: 7,022,340

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
BrazilPI0412905► Subscribe
Canada2490335► Subscribe
China1826099► Subscribe
Germany60301351► Subscribe
Denmark1500390► Subscribe
European Patent Office1500390► Subscribe
Spain2243840► Subscribe
Hong Kong1072009► Subscribe
Israel187591► Subscribe
Japan2007517762► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Teva
Express Scripts
Harvard Business School
Federal Trade Commission
Colorcon
Deloitte
Chubb
Boehringer Ingelheim
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot